Comparison · NCT00091949-daf8f763
Pioglitazone vs Placebo: Recurrent Fatal or Non-fatal Stroke, or Fatal or Non-fatal Myocardial Infarction
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Pioglitazone vs Placebo: Recurrent Fatal or Non-fatal Stroke, or Fatal or Non-fatal Myocardial Infarction. Trial comparisons, record NCT00091949-daf8f763. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00091949-daf8f763
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0903 | 0.0783 | 0.104 | wilson | |
| Risk in group 2 | 0.118 | 0.104 | 0.133 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0275 | -0.0467 | -0.00824 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.767 | 0.636 | 0.924 | log | |
| Odds ratio, group 1 over group 2 | 0.744 | 0.604 | 0.915 | log | |
| Number needed to treat, for one fewer participant with the outcome on Pioglitazone than on Placebo | 36.4 | 21.4 | 121 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Pioglitazone | pioglitazone: a thiazolidinedione drug | 175 | 1,939 | OG000 |
| Group 2 | Placebo | placebo: an inactive substance | 228 | 1,937 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Recurrent Fatal or Non-fatal Stroke, or Fatal or Non-fatal Myocardial Infarction
- Description
- Time frame
- Up to 5 years
- Population
Source ClinicalTrials.gov
Trial
- Title
- Insulin Resistance Intervention After Stroke Trial
- NCT number
- NCT00091949
- Phases
- PHASE3
- Conditions
- Stroke, Myocardial Infarction, Diabetes
- Interventions
- pioglitazone, placebo
- Lead sponsor
- Yale University
- Results first posted
- 2016-10-28
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00091949?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00091949-daf8f763